Pharma/Biotech - Page 1 | TalkMarkets
All Posts > Content under Pharma/Biotech
1 to 16 of 2062 Posts
1 2 3 ... 129
Don’t Buy Biotech Sector’s Rally … Yet
Article By: Chad Shoop
Monday, August 21, 2017 7:52 PM EDT
In the coming weeks, one sector - biotech - is going to pop 10%, 15% or more. And when it happens, everyone you know will be telling you that now is the time to buy these stocks.But this isn’t the right time to buy into this sector.
In this article: IBB Also: BIIB, CELG, GILD
Seeking Confirmations – US Stock Market
Article By: Gary Tanashian
Sunday, August 20, 2017 5:40 PM EDT
We have several inputs forecasting change (market pivots) ranging from seasonal tendencies to an expected US dollar rally, Fed monetary tightening, the 30 month S&P 500 cycle, not to mention a presidential administration in utter disarray.
In this article: MDT, TMO, IBB, GLD, IHI, XLV, SPX
10 Undervalued Stocks For The Enterprising Investor – August 2017
Article By: Benjamin Clark
Sunday, August 20, 2017 5:01 PM EDT
Using the ModernGraham Valuation Model, I’ve selected the ten most undervalued companies. Each company has been determined to be suitable for the Enterprising Investor.
In this article: AHL, FL, KBH, KORS, LYB, SIG, GILD, NAVI, LNR, LUC
Income Trade Opportunity For 12% In 28 Days
Article By: Greg Group
Saturday, August 19, 2017 7:47 PM EDT
Option selling offers another method to diversify investing strategies beyond traditional dividend investing. We have combined technical stock events with our strategy to identify high returns option selling opportunities.
In this article: ONCE
Disruption Of Confidence
Article By: Lance Roberts
Saturday, August 19, 2017 4:18 PM EDT
This is not a market currently to be trifled with as the overbought and overly bullish conditions remain at extremes. The time for complacency within portfolio allocations and risk management may be coming to an end.
In this article: SLY, VEA, MDY, SPY, VNQ, XLB, XLE, XLF, XLI, XLV, XLY
The CBD Market Could Reach $2.1 Billion By 2020
Article By: Technical420
Friday, August 18, 2017 5:29 PM EDT
It is estimated that the CBD market will grow to $2.1 billion market in consumer sales by 2020. Perhaps even more interesting was the guess that roughly 25% of those CBD sales would be derived from industrial hemp.
Biotech Digest – GMED Receives Clearance, BIOC Inks New Collaboration, PFE Receives Approval
Article By: KKD Healthcare Analytics
Friday, August 18, 2017 2:03 PM EDT
Globus Medical Inc. stock perked up as the company announced receiving the 510 (k) clearance from the FDA for Excelsius GPS. AstraZeneca announced receiving the FDA approval for its Lynparzaa. Pfizer has FDA approval for its Besponsa.
Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection
Article By: The Life Sciences Report
Thursday, August 17, 2017 1:17 PM EDT
Inovio Pharmaceuticals Inc. exited Q2/17 with $92 million in cash. It has closed a public offering that yielded $70.5 million, which "would be used for general corporate purposes, including clinical trial expenses.
In this article: INO
The Cannabis Distribution Quagmire In Nevada Has Caused A Sharp Decline In Sales
Article By: Technical420
Thursday, August 17, 2017 1:09 PM EDT
Shortly after Nevada's recreational marijuana program launched in July, a state of emergency was reported when dispensaries did not have enough product to support demand.
In this article: VPGDF
Can Pfizer Bank On New Immunotherapy Bavencio For Growth?
Article By: Zacks Investment Research
Thursday, August 17, 2017 12:59 PM EDT
As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc.’s newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant.
In this article: PFE Also: AZN, MRK, NVS
Of Pharma Drug Approvals, Global Updates, Oil Prices, And Top Stocks In Action Today
Article By: Equitymaster India
Thursday, August 17, 2017 2:23 AM EDT
Indian share markets snapped their losing streak seen during last week and closed their Wednesday session on a positive note.
Why Diligence Matters: Don’t Buy Acadia Healthcare’s Roll-Up
Article By: David Trainer
Wednesday, August 16, 2017 12:48 PM EDT
Acadia operates in the Behavioral Healthcare field, which focuses on treating people with mental illness and addiction. The industry is fairly fragmented, and the bull case for Acadia has rested on the idea that it can reap gains.
In this article: ACHC
Three Reasons Marijuana Stocks Are A Risky Investment
Article By: Modest Money
Tuesday, August 15, 2017 2:46 PM EDT
With the legalization of marijuana in many US states comes a unique opportunity for investors. People can now invest in what is being called marijuana stocks. What are the risks of investing in something so new and different?
E 20 Questions For NuLife Sciences CEO John B. Hollister
Article By: Terry Chrisomalis
Tuesday, August 15, 2017 12:26 PM EDT
An inside look at a small company looking to have a big impact in transplant technology.
In this article: NULF
Canadian Cannabis Stocks Trade Higher On Earnings
Article By: Technical420
Tuesday, August 15, 2017 12:17 PM EDT
Earnings season has started to heat up for marijuana stocks and we have seen several companies report earnings that have shown significant growth.
In this article: SRNA, TWMJF, MEDFF
Otonomy Seen Rallying Up To 95% On Positive Meniere's Disease Data
Article By: The Fly
Tuesday, August 15, 2017 11:40 AM EDT
JPMorgan this morning upgraded Otonomy (OTIC) to Overweight from Neutral, saying that the stock could rise up to 95% if the results of an upcoming trial of its Otividex drug are positive.
In this article: OTIC
1 to 16 of 2062 Posts
1 2 3 ... 129